Pfizer Completes Enrollment in SPIRE-2 Trial for Cardiovascular Therapy Bococizumab
Patient enrollment is complete in Pfizer’s global SPIRE-2 clinical trial, which will be evaluating the efficacy of bococizumab in reducing cardiovascular events, according to a Pfizer announcement. Cardiovascular disease is the ... Read more